Which antibiotics are associated with nephrotoxicity?

Antibiotics Associated with Nephrotoxicity

The antibiotics most commonly associated with nephrotoxicity include aminoglycosides (amikacin, kanamycin, streptomycin, gentamicin, tobramycin), polymyxins (colistin, polymyxin B), capreomycin, amphotericin B, vancomycin (especially when combined with piperacillin/tazobactam), certain beta-lactams (cephaloridine, cephaloglycin, imipenem), and foscarnet.

High-Risk Nephrotoxic Antibiotics

Aminoglycosides

The aminoglycoside class represents the most extensively documented nephrotoxic antibiotics in clinical practice:

• Amikacin and kanamycin: These agents are more nephrotoxic than streptomycin 1. Renal impairment occurs in 8.7% of patients receiving amikacin, with higher rates (versus 3.4% in patients without risk factors) in those with baseline elevated creatinine, larger cumulative doses, or concurrent nephrotoxic agents 1.

• Streptomycin: Nephrotoxicity occurs less commonly than with amikacin or kanamycin, with renal insufficiency requiring discontinuation in approximately 2% of patients 1.

• Gentamicin and tobramycin: While eighth cranial nerve toxicity is well-documented with these agents, nephrotoxicity remains a significant concern, particularly with prolonged therapy 2, 3.

Key mechanism: Aminoglycosides enter proximal tubular cells and accumulate in lysosomes, causing phospholipid buildup that inhibits lysosomal function and leads to tubular necrosis 4.

Polymyxins

• Colistin and polymyxin B: The pooled incidence of polymyxin-induced nephrotoxicity is 45% overall 5. Colistin demonstrates higher nephrotoxicity (48%) compared to polymyxin B (38%), with colistin carrying a 37% increased risk of developing nephrotoxicity 5.

Second-Line Injectable Agents

• Capreomycin: Significant renal toxicity requiring drug discontinuation occurs in 20-25% of patients 1. Nephrotoxic effects include reduced creatinine clearance, potassium and magnesium depletion, and proteinuria 1.

Antifungals

• Amphotericin B: Conventional amphotericin B causes significant nephrotoxicity through direct tubular damage 6. Liposomal preparations are equally effective but less nephrotoxic 6.

Glycopeptides

• Vancomycin: Particularly nephrotoxic when combined with piperacillin/tazobactam, showing significantly higher odds of acute kidney injury (OR 3.861) compared to vancomycin combined with other antipseudomonal beta-lactams like cefepime or meropenem 7.

Beta-Lactams

Certain beta-lactams cause acute proximal tubular necrosis 8:

• Cephaloridine and cephaloglycin: No longer used clinically due to severe nephrotoxicity
• Imipenem: Marketed with nephroprotective renal transport inhibitors (cilastatin) to mitigate toxicity 8

Antivirals

• Foscarnet: Causes nephrotoxicity and multiple serum electrolyte abnormalities (hypocalcemia, hypophosphatemia, hypomagnesemia, hypokalemia) 3.

Risk Factors for Antibiotic-Induced Nephrotoxicity

The following factors significantly increase nephrotoxicity risk:

• Advanced age: Each year increases odds by 3% (AOR 1.03) 5
• Higher daily doses: 46% increased risk (AOR 1.46) 5
• Underlying diabetes mellitus: 81% increased risk (AOR 1.81) 5
• Concomitant nephrotoxic drugs: 131% increased risk (AOR 2.31) 5
• Pre-existing renal impairment: Dramatically increases risk across all nephrotoxic antibiotics 1
• Low serum albumin: Protective effect with higher albumin (AOR 0.69) 5

Critical Clinical Pitfalls

The "Triple Whammy" Effect

Combining multiple nephrotoxins exponentially increases AKI risk. Each additional nephrotoxin presents 53% greater odds of developing AKI 9. Escalating from two to three nephrotoxic medications more than doubles AKI risk, with 25% of patients receiving three or more nephrotoxins developing AKI 9.

Monitoring Inadequacies

Traditional markers like serum creatinine are unreliable for early detection 10. Monthly monitoring of renal function is essential for aminoglycosides and other nephrotoxic agents 1, 3.

Pregnancy Considerations

Aminoglycosides (amikacin, kanamycin, streptomycin, gentamicin, tobramycin) and capreomycin are contraindicated in pregnancy due to fetal nephrotoxicity and congenital hearing loss 1, 2.

Dosing Adjustments in Renal Impairment

For aminoglycosides in patients with renal insufficiency 1:

• Reduce dosing frequency to 2-3 times weekly
• Maintain dose at 12-15 mg/kg to preserve concentration-dependent bactericidal effect
• Administer after dialysis
• Monitor serum drug concentrations to avoid toxicity

Prevention Strategies

Primary prevention 6, 9:

• Use single daily dosing for aminoglycosides rather than multiple daily doses in patients with normal kidney function
• Select less nephrotoxic alternatives when therapeutically equivalent
• Avoid combining nephrotoxic agents whenever possible
• Use topical or aerosolized aminoglycosides rather than IV administration when feasible

Monitoring requirements 3, 6:

• Monitor aminoglycoside drug levels when multiple daily dosing exceeds 24 hours
• Monitor single-daily dosing when treatment exceeds 48 hours
• Perform monthly renal function assessments during prolonged therapy